SCHEDULE: Ally Bridge Group Takes 11.3% Stake in ProMIS Neurosciences, Appoints Director

Ally Bridge Group entities and Fan Yu disclose an 11.3% beneficial ownership in ProMIS Neurosciences Inc. and the appointment of Slanix Paul Alex to the Board of Directors.

Summary

• Ally Bridge Group entities (ABG Management Ltd., Ally Bridge Group (NY) LLC, Ally Bridge MedAlpha Master Fund L.P.) and Mr. Fan Yu collectively beneficially own 6,070,405 Common Shares of ProMIS Neurosciences Inc.
• This ownership represents 11.3% of the Issuer's outstanding Common Shares, based on 53,811,110 shares as of September 26, 2025.
• The beneficially owned shares include 6,058,738 Common Shares held by Ally Bridge MedAlpha Master Fund L.P. and 11,667 Common Shares underlying vested employee stock options granted to Dr. Alex.
• Ally Bridge MedAlpha Master Fund L.P. purchased 6,058,738 Common Shares and warrants for 9,690,037 Common Shares for an aggregate consideration of $10,509,277.
• Slanix Paul Alex, President and Portfolio Manager of Public Equity at Ally Bridge Group, was appointed to ProMIS Neurosciences Inc.'s Board of Directors effective October 22, 2025.
• The Reporting Persons have entered into three Registration Rights Agreements (2023, 2024, 2025) with the Issuer, requiring the Issuer to file registration statements for the resale of Common Shares underlying purchased securities and warrants.
• The Reporting Persons acquired these securities for investment purposes and may review their investments, acquire or sell additional securities, and engage in discussions regarding potential extraordinary corporate transactions.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to a significant institutional investment and the appointment of a representative to the board, suggesting increased oversight and potential strategic initiatives. However, the filing is primarily an ownership disclosure, not a performance report, limiting a stronger positive assessment.

Positives

• Significant institutional investment by Ally Bridge Group, indicating confidence in ProMIS Neurosciences Inc.'s prospects.
• Appointment of Slanix Paul Alex, a senior executive from Ally Bridge Group, to the Board of Directors, potentially bringing valuable strategic oversight and expertise.
• Registration Rights Agreements facilitate future liquidity for the Reporting Persons, which can be a positive signal for other investors regarding potential future trading activity.

Risks

• The Reporting Persons explicitly state their intent to review investments and potentially explore extraordinary corporate transactions, such as mergers, reorganizations, take-private transactions, sales or acquisitions of assets/businesses, changes to capitalization or dividend policy, or changes in management or Board composition, which introduces strategic uncertainty for existing shareholders.
• The 9,690,037 Common Shares issuable upon exercise of warrants held by Ally Bridge MedAlpha Master Fund L.P. are subject to limitations on exercise, which could affect the timing and extent of their conversion into common stock.

Future Outlook

The Reporting Persons intend to continuously review their investment in ProMIS Neurosciences Inc. and may acquire additional securities, sell existing holdings, or engage in discussions with management, the Board, and other stakeholders. They may also explore extraordinary corporate transactions such as mergers, reorganizations, take-private transactions, asset sales, changes to capitalization or dividend policy, or alterations to management or Board composition.

Industry Context

This filing reflects a significant institutional investor taking a substantial stake and board representation in a neuroscience company, which is common in the biotechnology sector where strategic investments and active oversight can be crucial for drug development and commercialization success.

Management Changes

Corporate Governance

Related Party Transactions

• Slanix Paul Alex, an executive of Ally Bridge Group, was appointed to the Board of Directors of ProMIS Neurosciences Inc., while Ally Bridge Group entities are significant shareholders.
• Dr. Alex was granted an employee stock option to purchase 40,000 Common Shares, with 25% vesting immediately and the remainder vesting monthly, for the benefit of Ally Bridge MedAlpha Master Fund L.P.

Stakeholder Impact

• Shareholders: Potential for increased strategic direction and oversight from a significant institutional investor, but also uncertainty regarding potential extraordinary corporate transactions.
• Company Management: Will likely engage in discussions with Ally Bridge Group regarding business, financial condition, operations, and strategic opportunities.
• Board of Directors: Gains a new member with ties to a major shareholder, potentially shifting dynamics and strategic focus.

Next Steps

• Reporting Persons may acquire additional securities of the Issuer or sell existing holdings.
• Reporting Persons may engage in discussions with management, the Board, and securityholders regarding the Issuer's business and strategic direction.
• Reporting Persons may explore extraordinary corporate transactions, including mergers, reorganizations, or changes in corporate structure.
• Dr. Alex's employee stock option will continue to vest in thirty-six equal monthly installments, subject to his continued service as a director.

Key Dates

Recommendation

The filing details a significant ownership stake by Ally Bridge Group and the appointment of one of their executives to the board. This indicates strong institutional interest and potential for future strategic initiatives or oversight, which could be beneficial. However, without financial performance data or specific strategic plans, a definitive 'buy' or 'sell' is premature. The 'hold' recommendation reflects the positive signal of institutional involvement balanced with the lack of immediate performance catalysts in this specific filing.

Keywords

ProMIS Neurosciences, Ally Bridge Group, Schedule 13D, Beneficial Ownership, Board Appointment, Institutional Investment, Biotechnology, Neuroscience, Warrants, Registration Rights